KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.90

The Preventive Effects of Boron-Based Gel on Radiation Dermatitis in Patients Being Treated for Breast Cancer: A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Fikrettin Sahin, Mohammad Bagher Pirouzpanah, Hossein Bijanpour, Mohammad Mohammadzadeh, Reza Eghdam Zamiri, Amir Ghasemi Jangjoo, Behnam Nasiri, Hojjatollah Saboori, Ayşegül Doğan, Selami Demirci, Erhan Ayşan, Ahmet Çağrı Büke, Ali Reza Naseri, Seyed Kazem Shakouri, Dawood Aghamohammadi, Mostafa Alizade-Harakiyan, Farshad Seyed Nejad

Oncol Res Treat 45(4) 197-204

PMID34979503
PMCID-
DOI10.1159/000520363
发表日期2022-01-03
入排依据:The study is a Phase III randomized controlled trial in oncology (breast cancer), but the intervention is a boron-based gel for preventing radiation dermatitis, not a drug intervention for cancer treatment. The endpoints are incidence of dermatitis, erythema, and desquamation after 14 days, which are categorical side-effect outcomes, not time-to-event efficacy endpoints (OS, PFS, DFS, etc.) as required.
摘要

摘要

INTRODUCTION: Radiation dermatitis (RD) is a side effect of radiation therapy (RT) which is experienced by over 90% of patients being treated for breast cancer. The current clinical trial was conducted to measure the preventative effects of a boron-based gel on several different clinical outcomes (dermatitis, erythema, dry desquamation, and moist desquamation) after 25 radiotherapy sessions. METHODS: This research used a double-blind parallel-group design with a placebo control (n = 76) and randomized group (n = 181), with all participants being between 18 and 75 years old. Fifteen minutes before each radiotherapy, participants in the intervention group were given a gel containing 3% sodium pentaborate pentahydrate, while those in the placebo group received a gel with no chemical substance. Dermatitis, erythema, dry desquamation, and moist desquamation were compared between the 2 groups. RESULTS: At baseline, there were no significant differences between the groups (p > 0.05), except for body mass index. After 14 days of treatment, dermatitis (98.7% vs. 9.9%; p < 0.001), erythema (96.1% vs. 12.2%; p < 0.001), dry desquamation (50% vs. 3.9%; p < 0.001), and moist desquamation (18.4% vs. 0.6%; p < 0.001) were much more common in the placebo group than the intervention group. To prevent dermatitis, erythema, dry desquamation, and moist desquamation in 1 patient, on average, 1.1 (95% confidence interval [CI]: 1.1-1.2), 1.2 (95% CI: 1.1-1.3), 2.2 (95% CI: 1.7-2.9), and 5.6 (95% CI: 3.8-11.0) patients need to be treated, respectively. CONCLUSION: The boron-based gel has a significant preventive effect on several categories of RD which might be used by clinicians in breast cancer.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。